A detailed history of Royal Bank Of Canada transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,303 shares of STOK stock, worth $51,765. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,303
Previous 3,345 28.64%
Holding current value
$51,765
Previous $45,000 15.56%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.24 - $15.92 $11,725 - $15,251
958 Added 28.64%
4,303 $52,000
Q2 2024

Aug 14, 2024

BUY
$11.03 - $17.52 $24,839 - $39,455
2,252 Added 206.04%
3,345 $45,000
Q1 2024

Nov 05, 2024

SELL
$4.12 - $14.17 $9,278 - $31,910
-2,252 Reduced 67.32%
1,093 $14,000
Q1 2024

May 15, 2024

SELL
$4.12 - $14.17 $26,578 - $91,410
-6,451 Reduced 85.51%
1,093 $14,000
Q4 2023

Feb 14, 2024

BUY
$3.37 - $5.4 $9,813 - $15,724
2,912 Added 62.87%
7,544 $39,000
Q3 2023

Nov 14, 2023

BUY
$3.78 - $11.99 $6,323 - $20,059
1,673 Added 56.54%
4,632 $18,000
Q2 2023

Aug 14, 2023

BUY
$7.93 - $13.82 $12,822 - $22,346
1,617 Added 120.49%
2,959 $31,000
Q1 2023

May 15, 2023

SELL
$7.65 - $10.38 $28,144 - $38,188
-3,679 Reduced 73.27%
1,342 $11,000
Q4 2022

Feb 14, 2023

BUY
$7.07 - $15.69 $32,995 - $73,225
4,667 Added 1318.36%
5,021 $46,000
Q3 2022

Nov 14, 2022

BUY
$12.56 - $22.53 $1,846 - $3,311
147 Added 71.01%
354 $5,000
Q2 2022

Aug 15, 2022

SELL
$10.36 - $23.93 $10,836 - $25,030
-1,046 Reduced 83.48%
207 $3,000
Q1 2022

May 16, 2022

SELL
$17.19 - $26.1 $48,046 - $72,949
-2,795 Reduced 69.05%
1,253 $27,000
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $44,369 - $75,264
2,450 Added 153.32%
4,048 $97,000
Q3 2021

Nov 15, 2021

BUY
$23.65 - $34.44 $6,882 - $10,022
291 Added 22.26%
1,598 $41,000
Q2 2021

Aug 16, 2021

BUY
$30.53 - $41.09 $39,902 - $53,704
1,307 New
1,307 $44,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $474M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.